Fate Starts Phase 1 Trial for FT825 / ONO-8250 in HER2-expressing Advanced Solid Tumors

 iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain

Phase 1 Study is Being Conducted in Collaboration with Ono Pharmaceutical

https://www.biospace.com/article/releases/fate-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-ft825-ono-8250-in-patients-with-her2-expressing-advanced-solid-tumors/